

## **Notice to Comply**

Application No. 09/832659 Examiner J.Seharaseyon

Applicant(s) White Co. **Art Unit** 

1647

**SEP 12 2003** 

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUEN CENTER 1600/296 **DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1116	requirements for such a disclosure as set for the of S.F. 1.0.2.1 - 1.0.2.5 for the following reason(s).
⊠	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other: CRF is flawed see the attached CRF problem report.
	plicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or <b>substitute</b> paper copy of the "Sequence Listing", as well as an amendment directing its ry into the <b>specification</b> .
app	A statement that the content of the paper and computer readable copies are the same and, where blicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 25(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212

Patent Software Program Support

Technical Assistance......703-287-0200

To Purchase Patent Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Atty. Docket No: BII-08EP 12 200

In re patent application of

WHITTY, ADRIAN et al.

**TECH CENTER 1600/290**0

Serial No. 09/832,659

Filed: April 11, 2001

For: INTERFERON-BETA FUSION PROTEINS AND USES

## STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Mail Stop SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

- the submission, filed herewith in accordance with 37
   C.F.R. § 1.821(g), does not include new matter;
- 2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Respectfully sybmitted,

James A. Coburn

HARBOR CONSULTING IP SERVICES, INC.

1500A Lafayette Road, #262

Portsmouth, N.H.

800-318-3021